FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation. Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health...

FORUS Therapeutics Inc. and PharmaEssentia Corporation have entered into an exclusive licensing agreement for the registration and distribution of BESREMi® (ropeginterferon alfa-2b) for the treatment of polycythemia vera (PV), in Canada. Under the terms of the...

FORUS Therapeutics is thrilled to welcome Karen Winkworth as Therapeutic Area Manager, Hematology/Oncology, GTA. Karen brings with her a proven track record of delivering superior value across therapeutic areas - including over 15 years in hematology and oncology....

FORUS Therapeutics is delighted to welcome Chris Mitton as Therapeutic Area Manager, Hematology/Oncology, Atlantic Canada. Chris joins FORUS with over 30 years experience as a pharmaceutical professional with extensive expertise across various therapeutic areas,...

In a remarkable decision posted earlier this month, INESSS stands alone in failing to recognize the therapeutic value of XPOVIO. This despite Health Canada approval, a positive CADTH decision, Quebec clinician and patient support and positive funding recommendations...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in PEI as of April 23rd. Please see the following links for full funding criteria:  PEI Pharmacare Bulletin – Pharmacist Bulletin – April 09, 2024 We are excited about these...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria: Ontario: Exceptional Access Program | ontario.ca Newfoundland...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Nova Scotia as of October 1st. Please see the following link for full funding criteria: Nova Scotia Pharmacare News Bulletins Pharmacy Edition (novascotia.ca) We are excited...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in British Columbia as of October 1, 2023. Further details on the criteria can be found here, under the MYBSD protocol: Lymphoma & Myeloma (bccancer.bc.ca) We are excited...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Saskatchewan as of September 1st. Please see the following link for full funding criteria: Drug Formulary (saskcancer.ca). We are excited about this important milestone for...

FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca). We are...

(Saint-lgnace-de-Stanbridge, Quebec) May 27th, 2023 – FORUS Therapeutics was a proud sponsor of the 11th Edition of the Défi Cyclo-Myélome. The Défi Cyclo-Myélome provides support to Dr. Richard LeBlanc, holder of the Université de Montréal Myeloma Canada Chair on...